Atossa CEO to Discuss Aging Diseases and Regulatory Pathways at ARDD…

Event summary

Atossa Therapeutics CEO Dr. Steven Quay to participate in ARDD 2026 panel on clinical trials and regulatory pathways for diseases of aging.
Panel to be held at Harvard University on October 1, 2026.
Discussion will focus on translating scientific evidence in aging into clinical development programs.
Other panelists include representatives from Novo Nordisk, Mass General Brigham, and UCLA.
Atossa's lead product candidate, (Z)-endoxifen, is in development for oncology and rare diseases.

The big picture

Atossa Therapeutics is positioning itself at the forefront of aging research and drug discovery, a field increasingly focused on translating scientific advancements into actionable therapies. The company's participation in the ARDD 2026 panel underscores its strategic emphasis on navigating complex regulatory pathways and designing effective clinical trials, critical components for success in the biopharmaceutical industry. As Atossa expands its pipeline, its ability to execute on these strategies will be key to its long-term growth and market positioning.

What we're watching

Regulatory Strategy: How Atossa's approach to clinical trials and regulatory pathways will impact the development timeline for (Z)-endoxifen.
Market Expansion: Whether Atossa can successfully expand its development efforts into rare diseases while maintaining focus on oncology.
Industry Collaboration: The pace at which Atossa can leverage partnerships with academic and industry leaders to advance its therapeutic candidates.